Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04188106 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment
A Phase 4 study, sponsored by Rose Research Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT04188106 is a Phase 4 study that has completed, run by Rose Research Center. The registered enrollment target is 26 participants.
The verdict
NCT04188106, a Phase 4 study, has completed, sponsored by Rose Research Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This open-label study will evaluate hydroxyzine, a first-generation antihistamine, combined with varenicline, to help smokers abstain from smoking during a 12-week trial period by diminishing the nausea, stress, anxiety, and sleep disturbances associated with the use of varenicline and with nicotine withdrawal.
Interventions
- DRUG Varenicline Pill
- DRUG Hydroxyzine Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2019-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04188106
The ClinicalTrials.gov registry entry for NCT04188106 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rose Research Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Varenicline Pill is the first listed.
NCT04188106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04188106 about?
NCT04188106 is a clinical study titled "Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment". This open-label study will evaluate hydroxyzine, a first-generation antihistamine, combined with varenicline, to help smokers abstain from smoking during a 12-week trial period by diminishing the nausea, stress, anxiety, and sleep disturbances associated with the use of varenicline and with nicotine...
What is the current status of trial NCT04188106?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2019-06-17. Estimated completion is 2019-12-15.
What interventions are being tested in trial NCT04188106?
The interventions under investigation include: Varenicline Pill (DRUG), Hydroxyzine Pill (DRUG).
Who is sponsoring clinical trial NCT04188106?
This trial is sponsored by Rose Research Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.